Market Overview:
The global blood derivative product market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of blood derivatives. Based on type, the global blood derivative product market is segmented into albumin, coagulation factor concentrates, immunoglobulins, and other products. The albumin segment is expected to account for the largest share of the market in 2018. This can be attributed to its wide range of applications in various medical treatments such as hemophilia A & B therapy and shock therapy. Based on application, the global blood derivative product market is segmented into platelet aggregation inhibitors, fibrinolytics agents anticoagulants agents), and other applications (such as erythropoietin). The platelet aggregation inhibitors segment accounted for the largest share of this market in 2017 owing to its growing demand for prophylactic use among patients with cardiovascular diseases (CVDs) across all regions.
Product Definition:
Blood derivative product is a product that is derived from blood. It can be used to treat a variety of medical conditions. It is important because it can help to improve the health of people who are suffering from various medical conditions.
Albumin:
Albumin is a type of protein, found in the human body. It has a molecular weight of 54.3 kilotons and is also known as the blood plasma protein or serum albumin. The main function of this protein is to maintain the correct level of fluid balance in our bodies by binding excess water and transporting hydrophobic drugs and proteins that would not otherwise be absorbed by cells.
Coagulation Factor Concentrates:
Coagulation factor concentrates are used in the preparation of blood derivatives. It is a complex mixture of proteins, which aids in the clotting of blood. The factors present in concentrated form are Fibrinogen, D-glucose (D-group), platelet poor plasma, prothrombin complex concentrate and cryoprecipitate. These products find application across various therapeutic areas such as hemostasis and oncology.
Application Insights:
Platelet aggregation inhibitors accounted for the largest revenue share in 2016 and is anticipated to maintain its dominance over the forecast period. The segment is projected to register a significant CAGR during the study period owing to increasing incidence of thrombosis, which predominantly results in death of blood cells. As per WHO, approximately 730,000 deaths occur every year due largely to cardiovascular diseases globally. Platelet aggregation inhibitors are used for various indications such as acute coronary syndrome (ACS) and stable angina pectoris (SABP).
The anticoagulants segment is expected witness lucrative growth during the forecast period owing primarily to rising number of patients suffering from coagulation disorders or conditions where blood does not clot normally. As per American Society of Hematology (ASH), an estimated 5 million people suffer from a bleeding disorder annually in U.S.
Regional Analysis:
North America dominated the global blood derivative product market in 2017. The presence of sophisticated healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare expenditure levels in this region are some of the major factors responsible for its large share.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving economic conditions in emerging countries such as India and China. Furthermore, an increase in sports activities has led to a rise in injuries among young adults which will boost demand for these products over the forecast period.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. As a result, there is an increased demand for blood derivatives products that can help in the treatment and management of these conditions.
- Technological advancements: The field of blood derivates product research and development is constantly evolving with new technologies being developed to improve their efficacy and safety profile. This has led to an increase in demand for these products from both healthcare professionals as well as patients alike.
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood Derivative Product Market Research Report
By Type
Albumin, Coagulation Factor Concentrates, Immunoglobulins, Other
By Application
Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants, Other
By Companies
GlaxoSmithKline, Pfizer, Inc, Bristol-Myers Squibb Company, Leo Pharma A/S, Sanofi, Fusion Health Care, AstraZeneca Plc, Baxter International Inc, BDI Pharma, SK Plasma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
146
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Blood Derivative Product Market Report Segments:
The global Blood Derivative Product market is segmented on the basis of:
Types
Albumin, Coagulation Factor Concentrates, Immunoglobulins, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer, Inc
- Bristol-Myers Squibb Company
- Leo Pharma A/S
- Sanofi
- Fusion Health Care
- AstraZeneca Plc
- Baxter International Inc
- BDI Pharma
- SK Plasma
Highlights of The Blood Derivative Product Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Albumin
- Coagulation Factor Concentrates
- Immunoglobulins
- Other
- By Application:
- Platelet Aggregation Inhibitors
- Fibrinolytics
- Anticoagulants
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood Derivative Product Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A blood derivative product is a product that is derived from human blood. Blood derivatives can include products such as plasma, platelets, red cells, and white cells.
Some of the key players operating in the blood derivative product market are GlaxoSmithKline, Pfizer, Inc, Bristol-Myers Squibb Company, Leo Pharma A/S, Sanofi, Fusion Health Care, AstraZeneca Plc, Baxter International Inc, BDI Pharma, SK Plasma.
The blood derivative product market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Blood Derivative Product Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Blood Derivative Product Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Blood Derivative Product Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Blood Derivative Product Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Blood Derivative Product Market Size & Forecast, 2020-2028 4.5.1 Blood Derivative Product Market Size and Y-o-Y Growth 4.5.2 Blood Derivative Product Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Albumin
5.2.2 Coagulation Factor Concentrates
5.2.3 Immunoglobulins
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Platelet Aggregation Inhibitors
6.2.2 Fibrinolytics
6.2.3 Anticoagulants
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Blood Derivative Product Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Blood Derivative Product Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Albumin
9.6.2 Coagulation Factor Concentrates
9.6.3 Immunoglobulins
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Platelet Aggregation Inhibitors
9.10.2 Fibrinolytics
9.10.3 Anticoagulants
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Albumin
10.6.2 Coagulation Factor Concentrates
10.6.3 Immunoglobulins
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Platelet Aggregation Inhibitors
10.10.2 Fibrinolytics
10.10.3 Anticoagulants
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Albumin
11.6.2 Coagulation Factor Concentrates
11.6.3 Immunoglobulins
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Platelet Aggregation Inhibitors
11.10.2 Fibrinolytics
11.10.3 Anticoagulants
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Albumin
12.6.2 Coagulation Factor Concentrates
12.6.3 Immunoglobulins
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Platelet Aggregation Inhibitors
12.10.2 Fibrinolytics
12.10.3 Anticoagulants
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Albumin
13.6.2 Coagulation Factor Concentrates
13.6.3 Immunoglobulins
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Platelet Aggregation Inhibitors
13.10.2 Fibrinolytics
13.10.3 Anticoagulants
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Blood Derivative Product Market: Competitive Dashboard
14.2 Global Blood Derivative Product Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Pfizer, Inc
14.3.3 Bristol-Myers Squibb Company
14.3.4 Leo Pharma A/S
14.3.5 Sanofi
14.3.6 Fusion Health Care
14.3.7 AstraZeneca Plc
14.3.8 Baxter International Inc
14.3.9 BDI Pharma
14.3.10 SK Plasma